Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells
Stefanie A. Hartsink-Segers,
Carla Exalto,
Matthew Allen,
Daniel Williamson,
Steven C. Clifford,
Martin Horstmann,
Huib N. Caron,
Rob Pieters,
Monique L. Den Boer
Affiliations
Stefanie A. Hartsink-Segers
Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam, The Netherlands;Kids Cancer Kinome Consortium, Villejuif, France
Carla Exalto
Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam, The Netherlands
Matthew Allen
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Daniel Williamson
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Steven C. Clifford
Kids Cancer Kinome Consortium, Villejuif, France;Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Martin Horstmann
The German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany;Clinic of Pediatric Hematology and Oncology, Research Institute Children’s Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Huib N. Caron
Kids Cancer Kinome Consortium, Villejuif, France;Department of Pediatric Oncology, Academic Medical Center/Emma Children’s Hospital, Amsterdam, The Netherlands
Rob Pieters
Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam, The Netherlands
Monique L. Den Boer
Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children’s Hospital, Rotterdam, The Netherlands;Kids Cancer Kinome Consortium, Villejuif, France
This study investigated Polo-like kinase 1, a mitotic regulator often over-expressed in solid tumors and adult hematopoietic malignancies, as a potential new target in the treatment of pediatric acute lymphoblastic leukemia. Polo-like kinase 1 protein and Thr210 phosphorylation levels were higher in pediatric acute lymphoblastic leukemia (n=172) than in normal bone marrow mononuclear cells (n=10) (P
